SARAH MCFERON: Open Payments
NPI 1902303183 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,771 in 69 payments from 10 companies in 2025. Trend: 2023 $1,548 · 2024 $1,443 · 2025 $1,771
Food & beverage: $1,771
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 18 | $711 |
| Gilead Sciences, Inc. | 16 | $378 |
| ABBVIE INC. | 13 | $225 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $182 |
| Ipsen Biopharmaceuticals, Inc | 6 | $121 |
| Eisai Inc. | 3 | $88 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Eton Pharmaceuticals, Inc. | 1 | $17 |
| Intra-Sana Laboratories | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $14 |
Products named: REZDIFFRA, MAVYRET, XIFAXAN, IQIRVO, Lenvima, OCALIVA, GALZIN, RELTONE 200 MG.
Industry payments across TX — which companies pay providers there.
